MX2021004036A - Anticuerpos biespecíficos dirigidos a exosomas. - Google Patents

Anticuerpos biespecíficos dirigidos a exosomas.

Info

Publication number
MX2021004036A
MX2021004036A MX2021004036A MX2021004036A MX2021004036A MX 2021004036 A MX2021004036 A MX 2021004036A MX 2021004036 A MX2021004036 A MX 2021004036A MX 2021004036 A MX2021004036 A MX 2021004036A MX 2021004036 A MX2021004036 A MX 2021004036A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
exosome
targeting
associated protein
targeting bispecific
Prior art date
Application number
MX2021004036A
Other languages
English (en)
Inventor
Matthew K Robinson
Michael John Morin
Original Assignee
Immunome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunome Inc filed Critical Immunome Inc
Publication of MX2021004036A publication Critical patent/MX2021004036A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los inventos descritos en el presente documento están enfocados a anticuerpos biespecíficos que son capaces de dirigirse selectivamente a exosomas, uniendo específicamente una primera proteína asociada a exosoma y al ligando 1 de muerte programada ("PD-L1") como una segunda proteína asociada a exosoma. Estos anticuerpos biespecíficos pueden interrumpir la supresión de la actividad antitumoral por parte de las células inmunitarias al dirigirse a exosomas derivados de células tumorales que inhiben la activación de las células T. Por tanto, los anticuerpos biespecíficos del invento pueden utilizarse en métodos para tratar cáncer.
MX2021004036A 2018-10-17 2019-10-17 Anticuerpos biespecíficos dirigidos a exosomas. MX2021004036A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746862P 2018-10-17 2018-10-17
PCT/US2019/056698 WO2020081786A1 (en) 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies

Publications (1)

Publication Number Publication Date
MX2021004036A true MX2021004036A (es) 2021-08-24

Family

ID=70284767

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004036A MX2021004036A (es) 2018-10-17 2019-10-17 Anticuerpos biespecíficos dirigidos a exosomas.

Country Status (11)

Country Link
US (1) US20210347895A1 (es)
EP (1) EP3866851A4 (es)
KR (1) KR20210091714A (es)
CN (1) CN113423425A (es)
AU (1) AU2019359877A1 (es)
BR (1) BR112021007469A2 (es)
CA (1) CA3116560A1 (es)
IL (1) IL282355A (es)
MX (1) MX2021004036A (es)
SG (1) SG11202103812RA (es)
WO (1) WO2020081786A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021003779A (es) 2018-10-02 2021-09-21 Immunome Inc Anticuerpos dirigidos a la epn1.
CN114354913A (zh) * 2021-12-31 2022-04-15 厦门大学 一种外泌体pd-l1糖基化检测方法
CN114990129B (zh) * 2022-05-11 2023-02-03 北京贝来生物科技有限公司 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
WO2023225613A2 (en) * 2022-05-18 2023-11-23 Immunome, Inc. Combination anti-epn1 and anti-pd-l1 antibody therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
EP4141032B1 (en) * 2014-11-20 2024-05-29 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
RU2018105846A (ru) * 2015-07-29 2019-08-28 Новартис Аг Комбинация антагониста pd-1 с ингибитором egfr
WO2017087280A1 (en) * 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CU24613B1 (es) * 2016-02-06 2022-07-08 Epimab Biotherapeutics Inc Proteínas de unión a inmunoglobulinas fabs en tandem (fit-ig) biespecíficas que se unen a cmet y egfr
DK3433273T3 (da) * 2016-03-25 2022-02-14 Biomunex Pharmaceuticals Binding af molekyler til cd38 og pd-l1
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质

Also Published As

Publication number Publication date
EP3866851A4 (en) 2022-11-02
CN113423425A (zh) 2021-09-21
EP3866851A1 (en) 2021-08-25
WO2020081786A1 (en) 2020-04-23
KR20210091714A (ko) 2021-07-22
IL282355A (en) 2021-05-31
BR112021007469A2 (pt) 2021-08-10
AU2019359877A1 (en) 2021-05-20
JP2022512734A (ja) 2022-02-07
CA3116560A1 (en) 2020-04-23
SG11202103812RA (en) 2021-05-28
US20210347895A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
MX2021004036A (es) Anticuerpos biespecíficos dirigidos a exosomas.
MX2022006447A (es) Anticuerpos anti-pd-1 novedosos.
SA518390862B1 (ar) Pd-l1 أجسام مضادة ضد
MX2019002474A (es) Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
PH12019501253A1 (en) Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12019500369A1 (en) Anti-tim-3 antibodies
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
MX2022011818A (es) Metodos y composiciones para el direccionamiento de canceres de celulas t.
MY199019A (en) Pd-1 antibodies
EA201890278A1 (ru) Антитела к pd-l1
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
WO2018102589A3 (en) Anti-hrs antibodies and combination therapies for treating cancers
EP3964527A3 (en) Combination therapy for cancer
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
PH12016501672A1 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
SG10201900015XA (en) Bispecific cd33 and cd3 binding proteins
WO2019094595A3 (en) Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
MX2019009848A (es) Proteínas que se unen a her2, nkg2d y cd16.
WO2019232409A9 (en) Methods for genome editing and activation of cells
MX2021015337A (es) Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
MX2021009079A (es) Metodos para tratar el mieloma multiple.
MX2020002036A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.